Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Accumulated Expenses (2016 - 2025)

Guided Therapeutics' Accumulated Expenses history spans 16 years, with the latest figure at $9000.0 for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 99.11% to $9000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $9000.0, a 99.11% decrease, with the full-year FY2025 number at $9000.0, down 99.11% from a year prior.
  • Accumulated Expenses hit $9000.0 in Q4 2025 for Guided Therapeutics, up from $8000.0 in the prior quarter.
  • Over the last five years, Accumulated Expenses for GTHP hit a ceiling of $4.9 million in Q1 2021 and a floor of $7000.0 in Q3 2023.
  • Historically, Accumulated Expenses has averaged $715047.2 across 5 years, with a median of $414500.0 in 2021.
  • Biggest five-year swings in Accumulated Expenses: plummeted 99.34% in 2023 and later soared 10400.0% in 2024.
  • Tracing GTHP's Accumulated Expenses over 5 years: stood at $49000.0 in 2021, then surged by 2444.9% to $1.2 million in 2022, then fell by 14.35% to $1.1 million in 2023, then decreased by 5.34% to $1.0 million in 2024, then plummeted by 99.11% to $9000.0 in 2025.
  • Business Quant data shows Accumulated Expenses for GTHP at $9000.0 in Q4 2025, $8000.0 in Q3 2025, and $8000.0 in Q2 2025.